The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2018. AMA PRA Category 1 Credits™ may be claimed only once between June 1, 2015, and the expiration date.

BCSC® volumes are designed to increase the physician’s ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim AMA PRA Category 1 Credits™ upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 12 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician’s own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers’ package inserts or other independent sources, and considered in light of the patient’s condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, Ophthalmology, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: From BCSC Section 5, Neuro-Ophthalmology. Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (Courtesy of Mark J. Greenwald, MD.)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved. No part of this publication may be reproduced without written permission.

Printed in the United States of America.
Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, Senior Secretary for Clinical Education
Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, Secretary for Lifelong Learning and Assessment
George A. Cioffi, MD, New York, New York, BCSC Course Chair

Section 12

Faculty

Colin A. McCannel, MD, Chair, Los Angeles, California
Neal H. Atebara, MD, Honolulu, Hawaii
Stephen Jae Kim, MD, Nashville, Tennessee
Brian C. Leonard, MD, Ottawa, Canada
Richard B. Rosen, MD, New York, New York
David Sarraf, MD, Los Angeles, California
Emmett Cunningham, Jr, MD, PhD, MPH, Consultant, Hillsborough, California
Graham E. Holder, PhD, Consultant, London, England

The Academy wishes to acknowledge the American Society of Retina Specialists (ASRS), the Macula Society, and the Retina Society for recommending faculty members to the BCSC Section 12 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

Committee on Aging: Helen Ka-Fun Li, MD, Houston, Texas

Vision Rehabilitation Committee: Joseph L. Fontenot, Daphne, Texas

Practicing Ophthalmologists Advisory Committee for Education: David J. Browning, MD, PhD, Primary Reviewer, Charlotte, North Carolina; Edward K. Isbey III, MD, Chair, Asheville, North Carolina; Alice L. Bashinsky, MD, Asheville, North Carolina; Robert G. Fante, MD, Denver, Colorado; Bradley D. Fouraker, MD, Tampa, Florida; Dasa V. Gangadhar, MD, Wichita, Kansas; Steven J. Grosser, MD, Golden Valley, Minnesota; James A. Savage, MD, Memphis, Tennessee
European Board of Ophthalmology: Alain Gaudric, MD, Chair, Paris, France; Catherine Creuzot-Garcher, MD, PhD, FEB, Liaison, Dijon, France; Bahram Bodaghi, MD, PhD, Paris, France; Giovanni Staurenghi, MD, Milan, Italy; Adnan Tufail, MBBS, MD, London, United Kingdom

The EBO wishes to acknowledge EURETINA for recommending reviewers to the EBO committee.

Financial Disclosures

Academy staff members who contributed to the development of this product state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the past 12 months, they have had the following financial relationships:

* Dr Bodaghi: Abbott Medical Optics (C), Allergan (C, S), Bausch + Lomb Surgical (C), Novartis Pharmaceuticals (S), Santen (C), Xoma (C)

* Dr Browning: Aerpio Therapeutics (S), Alimera Sciences (C), Diabetic Retinopathy Clinical Research Network (S), Genentech (S), Novartis Pharmaceuticals (S), Pfizer (S), Regeneron Pharmaceuticals (S)

* Dr Creuzot-Garcher: Alcon Laboratories (C, S), Bausch + Lomb (C), Laboratoires Thea (C), Novartis Pharmaceuticals (C, L, S)

* Dr Fante: Ophthalmic Mutual Insurance Company (C)

* Dr Fouraker: Addition Technology (C), Alcon Laboratories (C), KeraVision (C), Ophthalmic Mutual Insurance Company (C)

* Dr Gaudric: Alcon Laboratories (C), Alimera Sciences (C), Bayer (C), Novartis Pharmaceuticals (C, S), ThromboGenics (C)

* Dr Grosser: Ivantis (O)

* Dr Holder: Servier (C), Isis Pharmaceuticals (C)

* Dr Isbey: Alcon Laboratories (S), Bausch + Lomb (S)

* Dr Leonard: Annidis (O), Bayer Healthcare Pharmaceuticals (C), Merck & Co (C), Novartis Pharmaceuticals (C), Orbis International (C), Pfizer (S), Regeneron Pharmaceuticals (C)

* Dr McCannel: DORC Dutch Ophthalmic Research Center (International)/Dutch Ophthalmic USA (C)

* Dr Rosen: Allergan (S), Clarity Medical Systems (C), Genentech (S), OD-OS (L), Optovue (C)

* Dr Sarraf: Alcon Laboratories (S), Allergan (S), DORC Dutch Ophthalmic Research Center (International)/Dutch Ophthalmic USA (S), Genentech (S), Heidelberg Engineering (L), Regeneron Pharmaceuticals (S), ThromboGenics (S)
Dr. Savage: Allergan (L)

Dr. Staurenghi: Alcon Laboratories (C, L), Allergan (C), Bayer (C, L), Canon (C), Glaxo-SmithKline (C), Heidelberg Engineering (C, L), Kowa (S), Novartis Pharmaceuticals (C, L, S), Ocular Instruments (P), OD-OS (C), Optos (C), Optovue (C), QLT Phototherapeutics (C), Roche (C), Zeiss (S)

Dr. Tufail: Alcon Laboratories (C), Allergan (C, L), Bayer Healthcare Pharmaceuticals (C), Genentech (C), Heidelberg Engineering (C), Notal Vision (S), Novartis Pharmaceuticals (C, L, S)

The other authors and reviewers state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

Recent Past Faculty

Richard S. Kaiser, MD
Adam A. Martidis, MD
Hermann D. Schubert, MD
David N. Zacks, MD, PhD

In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

American Academy of Ophthalmology Staff

Dale E. Fajardo, Vice President, Education
Beth Wilson, Director, Continuing Professional Development
Ann McGuire, Acquisitions and Development Manager
Stephanie Tanaka, Publications Manager
D. Jean Ray, Production Manager
Kimberly Torgerson, Publications Editor
Beth Collins, Medical Editor
Naomi Ruiz, Publications Specialist

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424
Contents

General Introduction .................................................. xv

Objectives ................................................................. 1

Introduction ................................................................. 3

PART I  Fundamentals and Diagnostic Approaches ..................... 5

1 Basic Anatomy ......................................................... 7

The Vitreous ............................................................... 7

Neurosensoric Retina .................................................. 8

Retinal Pigment Epithelium ........................................... 15

Bruch Membrane ....................................................... 17

Choroid ................................................................. 17

Sclera ................................................................. 18

2 Diagnostic Approach to Retinal Disease ......................... 21

Techniques of Examination ........................................... 21

Ophthalmoscopy ......................................................... 22

Imaging Technologies .................................................. 22

Scanning Laser Ophthalmoscopy ................................... 23

Optical Coherence Tomography ..................................... 26

Fundus Autofluorescence ............................................. 28

Retinal Angiographic Techniques ................................ 34

B-Scan Ultrasonography .............................................. 37

3 Retinal Physiology and Psychophysics .............................. 37

Electroretinography ................................................... 37

Full-Field (Ganzfeld) ERG ............................................ 38

Multifocal ERG ........................................................ 42

Pattern ERG ............................................................. 42

Clinical Considerations ............................................... 42

Electro-oculography .................................................... 44

Visual Evoked Cortical Potentials ................................ 46

Psychophysical Testing ............................................... 47

Contrast Sensitivity ..................................................... 48

Color Vision ............................................................. 49

Dark Adaptation ........................................................ 52

Photostress Recovery Time .......................................... 53
PART II  Disorders of the Retina and Vitreous        55

4 Age-Related Macular Degeneration and Other
   Causes of Choroidal Neovascularization       57
   Age-Related Macular Degeneration              57
   Genetics and AMD                             58
   Nonneovascular AMD                           59
   Neovascular AMD                              66
   Other Causes of Choroidal Neovascularization 79
      Ocular Histoplasmosis Syndrome             79
      Angioid Streaks                           81
      Pathologic Myopia                         82
      Idiopathic CNV and Miscellaneous Causes of CNV 83

5 Retinal Vascular Disease: Diabetic Retinopathy    85
   Terminology and Classification             85
      Diabetes Terminology                    85
      Diabetic Retinopathy Terminology         85
   Epidemiology of Diabetic Retinopathy      86
      The Wisconsin Epidemiologic Study of Diabetic Retinopathy  86
   Pathogenesis of Diabetic Retinopathy      87
   Systemic Medical Management of Diabetic Retinopathy 88
   Abnormalities Associated With Vision Loss From Diabetic
      Retinopathy                              92
      Nonproliferative Diabetic Retinopathy    92
         Diabetic Macular Edema                92
         Diabetic Macular Ischemia             100
      Severe Nonproliferative Diabetic Retinopathy  100
      Proliferative Diabetic Retinopathy.      101
         Management of Proliferative Diabetic Retinopathy and Its
            Complications                     102
      Vitrectomy Surgery for Complications of Diabetic Retinopathy  106
   Cataract Surgery in Patients With Diabetes Mellitus 107
   Recommended Diabetes-Related Ophthalmic Examinations 108

6 Retinal Vascular Diseases Associated With
   Cardiovascular Disease                     111
   Systemic Arterial Hypertension             111
      Hypertensive Retinopathy                111
      Hypertensive Choroidopathy              113
      Hypertensive Optic Neuropathy           113
   Retinal Vein Occlusion                     115
      Branch Retinal Vein Occlusion            117
      Central Retinal Vein Occlusion           120
   Ocular Ischemic Syndrome and Retinopathy of Carotid Occlusive
      Disease                                127
      Symptoms and Signs.                     127
9 Choroidal Disease ................................................................. 169
   Central Serous Chorioretinopathy ..................................... 169
   Optical Coherence Tomography ......................................... 170
   Fluorescein Angiography ................................................. 170
   Indocyanine Green Angiography ....................................... 172
   Fundus Autofluorescence Imaging ...................................... 172
   Differential Diagnosis ..................................................... 172
   Natural Course and Management ...................................... 173
Choroidal Perfusion Abnormalities ......................................... 173
   Increased Venous Pressure .............................................. 174
   Hypertension .................................................................... 174
   Inflammatory Conditions .................................................. 176
   Thromboembolic Disease .................................................. 177
   Iatrogenic Abnormalities .................................................. 177
Choroidal Hemangiomas ......................................................... 177
Uveal Effusion Syndrome ....................................................... 179
Bilateral Diffuse Uveal Melanocytic Proliferation ....................... 180

10 Focal and Diffuse Choroidal and Retinal Inflammation ............... 183
   Noninfectious Retinal and Choroidal Inflammation ................ 183
      White Dot Syndromes .................................................. 183
      Chorioretinal Autoimmune Conditions .............................. 191
      Sympathetic Ophthalmia .............................................. 195
      Uveitis Masquerade: Intraocular Lymphoma ...................... 195
Infectious Retinal and Choroidal Inflammation ............................ 196
   Cytomegalovirus Retinitis ............................................. 196
   Non-CMV Necrotizing Herpetic Retinitis ............................... 197
   Endogenous Bacterial Endophthalmitis ................................ 199
   Fungal Endophthalmitis .................................................. 200
   Tuberculosis ..................................................................... 202
   Syphilitic Chorioretinitis ............................................... 203
   Cat-Scratch Disease ...................................................... 204
   Toxoplasmic Retinochoroiditis .......................................... 204
   Toxocariasis .................................................................... 206
   Lyme Disease ................................................................... 207
   Diffuse Unilateral Subacute Neuroretinitis ......................... 207
   West Nile Virus Chorioretinitis ....................................... 208

11 Congenital and Stationary Retinal Disease ................................. 209
   Color Vision (Cone System) Abnormalities ......................... 209
   Congenital Color Deficiency ............................................. 209
   Night Vision (Rod System) Abnormalities ............................. 211
   Congenital Night-Blinding Disorders With Normal Fundi .......... 211
   Congenital Night-Blinding Disorders With Fundus Abnormality .... 213
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12 Hereditary Retinal and Choroidal Dystrophies</strong></td>
<td></td>
</tr>
<tr>
<td>Diagnostic and Prognostic Testing</td>
<td>215</td>
</tr>
<tr>
<td>Diffuse Photoreceptor Dystrophies</td>
<td>216</td>
</tr>
<tr>
<td>Retinitis Pigmentosa</td>
<td>217</td>
</tr>
<tr>
<td>Leber Congenital Amaurosis</td>
<td>218</td>
</tr>
<tr>
<td>Cone Dystrophies</td>
<td>223</td>
</tr>
<tr>
<td>Macular Dystrophies</td>
<td>224</td>
</tr>
<tr>
<td>Stargardt Disease</td>
<td>226</td>
</tr>
<tr>
<td>Vitelliform Degenerations</td>
<td>227</td>
</tr>
<tr>
<td>Early-Onset Drusen</td>
<td>230</td>
</tr>
<tr>
<td>Pattern Dystrophies</td>
<td>232</td>
</tr>
<tr>
<td>Sorsby Macular Dystrophy</td>
<td>233</td>
</tr>
<tr>
<td>Choroidal Dystrophies</td>
<td>234</td>
</tr>
<tr>
<td>Diffuse Degenerations</td>
<td>234</td>
</tr>
<tr>
<td>Regional and Central Choroidal Dystrophies</td>
<td>235</td>
</tr>
<tr>
<td>Inner Retinal and Vitreoretinal Dystrophies</td>
<td>237</td>
</tr>
<tr>
<td>X-Linked Retinoschisis</td>
<td>237</td>
</tr>
<tr>
<td>Enhanced S-Cone Syndrome</td>
<td>238</td>
</tr>
<tr>
<td><strong>13 Retinal Degenerations Associated With Systemic Disease</strong></td>
<td>239</td>
</tr>
<tr>
<td>Retinal Degeneration With Systemic Involvement</td>
<td>239</td>
</tr>
<tr>
<td>Infantile-Onset to Early Childhood–Onset Syndromes</td>
<td>239</td>
</tr>
<tr>
<td>Bardet-Biedl Syndrome</td>
<td>242</td>
</tr>
<tr>
<td>Hearing Loss and Pigmentary Retinopathy: Usher Syndrome</td>
<td>243</td>
</tr>
<tr>
<td>Neuromuscular Disorders</td>
<td>244</td>
</tr>
<tr>
<td>Other Organ System Disorders</td>
<td>244</td>
</tr>
<tr>
<td>Paraneoplastic and Autoimmune Retinopathies</td>
<td>246</td>
</tr>
<tr>
<td>Metabolic Diseases</td>
<td>247</td>
</tr>
<tr>
<td>Albinism</td>
<td>247</td>
</tr>
<tr>
<td>Central Nervous System Metabolic Abnormalities</td>
<td>248</td>
</tr>
<tr>
<td>Amino Acid Disorders</td>
<td>253</td>
</tr>
<tr>
<td>Mitochondrial Disorders</td>
<td>254</td>
</tr>
<tr>
<td><strong>14 Systemic Drug-Induced Retinal Toxicity</strong></td>
<td>257</td>
</tr>
<tr>
<td>Drugs Causing Abnormalities of the Retinal Pigment</td>
<td></td>
</tr>
<tr>
<td>Epithelium/Photoreceptor Complex</td>
<td>257</td>
</tr>
<tr>
<td>Chloroquine Derivatives</td>
<td>257</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td>259</td>
</tr>
<tr>
<td>Miscellaneous Medications</td>
<td>260</td>
</tr>
<tr>
<td>Drugs Causing Occlusive Retinopathy or Microvasculopathy</td>
<td>262</td>
</tr>
<tr>
<td>Drugs Causing Ganglion Cell and Optic Nerve Toxicity</td>
<td>262</td>
</tr>
<tr>
<td>Drugs Causing Macular Edema</td>
<td>263</td>
</tr>
<tr>
<td>Drugs Causing Crystalline Retinopathy</td>
<td>264</td>
</tr>
<tr>
<td>Drugs Causing Abnormalities in Color Vision and Electroretinography</td>
<td>266</td>
</tr>
<tr>
<td>Miscellaneous Drugs Causing Ocular Toxicities</td>
<td>266</td>
</tr>
</tbody>
</table>
15 Retinal Detachment and Predisposing Lesions ........ 267
Retinal Breaks ........................................ 267
Traumatic Breaks ..................................... 268
Trauma in Young Eyes ................................. 268
Posterior Vitreous Detachment ...................... 269
Examination and Management of Posterior Vitreous Detachment .... 271
Lesions Predisposing Eyes to Retinal Detachment ........ 272
Lattice Degeneration .................................. 272
Vitreoretinal Tufts .................................... 273
Meridional Folds, Enclosed Ora Bays, and Peripheral Retinal
Excavations ........................................... 274
Lesions Not Predisposing Eyes to Retinal Detachment .......... 275
Paving-Stone Degeneration ............................. 275
Retinal Pigment Epithelial Hyperplasia .................. 275
Retinal Pigment Epithelial Hypertrophy ................ 276
Peripheral Cystoid Degeneration ....................... 276
Prophylactic Treatment of Retinal Breaks ................ 276
Symptomatic Retinal Breaks ............................ 277
Asymptomatic Retinal Breaks .......................... 277
Lattice Degeneration .................................. 278
Aphakia and Pseudophakia .............................. 278
Fellow Eye in Patients With Retinal Detachment ........... 278
Subclinical Retinal Detachment ......................... 278
Retinal Detachment ..................................... 279
Rhegmatogenous Retinal Detachment .................... 279
Tractional Retinal Detachment .......................... 283
Exudative Retinal Detachment ........................... 283
Differential Diagnosis of Retinal Detachment .............. 284
Retinoschisis ......................................... 284
Differentiation of Retinoschisis From Rhegmatogenous
Retinal Detachment .................................... 285
Macular Lesions Associated With Retinal Detachment ........ 286
Optic Pit Maculopathy ................................ 286
Macular Holes in High Myopia .......................... 287

16 Diseases of the Vitreous and Vitreoretinal
Interface ................................................ 289
Posterior Vitreous Detachment .......................... 289
Epiretinal Membranes .................................. 290
Vitreomacular Traction Diseases ......................... 293
Idiopathic Macular Holes ............................... 294
Developmental Abnormalities ............................ 297
Tunica Vasculosa Lentis ................................ 297
Prepapillary Vascular Loops ............................. 297
Persistent Fetal Vasculature .............................. 298
Hereditary Hyaloideoretinopathies With Optically Empty Vitreous:
  Wagner and Stickler Syndromes ........................................... 299
Familial Exudative Vitreoretinopathy ...................................... 300
Vitreous Opacities .............................................................. 301
  Asteroid Hyalosis ............................................................. 301
  Vitreous Hemorrhage ....................................................... 302
  Pigment Granules ............................................................ 302
  Cholesterolosis ............................................................... 302
  Amyloidosis ..................................................................... 303
Vitreous Abnormalities Secondary to Surgery. .............................. 304

17 Posterior Segment Manifestations of Trauma ............................. 305
  Evaluation of the Patient After Ocular Trauma ......................... 305
  Blunt Trauma ................................................................. 306
    Vitreous Hemorrhage ...................................................... 307
    Comminuted Retinae ....................................................... 307
    Choroidal Rupture .......................................................... 307
    Posttraumatic Macular Hole .............................................. 309
    Traumatic Chorioretinal Disruption (Retinal Sclopetaria) ......... 311
    Scleral Rupture ............................................................. 311
Lacerating and Penetrating Injuries .......................................... 312
Perforating Injuries .............................................................. 313
Intraocular Foreign Bodies ..................................................... 313
  Surgical Techniques for Removal of Intraocular Foreign Bodies ... 315
  Retained Intraocular Foreign Bodies ...................................... 315
Posttraumatic Endophthalmitis ................................................. 316
Sympathetic Ophthalmia .......................................................... 317
Abusive Head Trauma ............................................................ 317
Avulsion of the Optic Disc ...................................................... 318
Phototoxicity ................................................................. 319
  Solar Retinopathy ............................................................ 320
  Phototoxicity From Ophthalmic Instrumentation ....................... 320
Occupational Light Toxicity ................................................... 321
Handheld Laser-Pointer Injury .................................................. 321

PART III Selected Therapeutic Topics .......................................... 323

18 Laser Therapy for Posterior Segment Diseases ......................... 325
  Basic Principles of Photocoagulation ...................................... 325
  Choice of Laser Wavelength ............................................... 325
  Practical Aspects of Laser Photocoagulation ............................ 327
  Complications of Photocoagulation ....................................... 330
  Transpupillary Thermotherapy ............................................. 332
  Photodynamic Therapy ...................................................... 332
  Complications of Photodynamic Therapy. ............................... 332
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td><strong>Vitreoretinal Surgery and Intravitreal Injections</strong></td>
<td>333</td>
</tr>
<tr>
<td></td>
<td>Pars Plana Vitrectomy</td>
<td>333</td>
</tr>
<tr>
<td></td>
<td>Vitrectomy for Selected Macular Diseases</td>
<td>334</td>
</tr>
<tr>
<td></td>
<td>Macular Epiretinal Membranes</td>
<td>334</td>
</tr>
<tr>
<td></td>
<td>Vitreomacular Traction Diseases</td>
<td>334</td>
</tr>
<tr>
<td></td>
<td>Submacular Hemorrhage</td>
<td>337</td>
</tr>
<tr>
<td></td>
<td>Vitrectomy for Complications of Diabetic Retinopathy</td>
<td>338</td>
</tr>
<tr>
<td></td>
<td>Vitreous Hemorrhage</td>
<td>338</td>
</tr>
<tr>
<td></td>
<td>Diabetic Tractional Retinal Detachment</td>
<td>339</td>
</tr>
<tr>
<td></td>
<td>Diabetic Macular Edema</td>
<td>340</td>
</tr>
<tr>
<td></td>
<td>Vitrectomy for Posterior Segment Complications of Anterior Segment Surgery</td>
<td>340</td>
</tr>
<tr>
<td></td>
<td>Postoperative Endophthalmitis</td>
<td>340</td>
</tr>
<tr>
<td></td>
<td>Retained Lens Fragments After Phacoemulsification</td>
<td>343</td>
</tr>
<tr>
<td></td>
<td>Posteriorly Dislocated Intraocular Lenses</td>
<td>345</td>
</tr>
<tr>
<td></td>
<td>Cystoid Macular Edema</td>
<td>345</td>
</tr>
<tr>
<td></td>
<td>Suprachoroidal Hemorrhage</td>
<td>345</td>
</tr>
<tr>
<td></td>
<td>Needle Penetration of the Globe</td>
<td>347</td>
</tr>
<tr>
<td></td>
<td>Rhegmatogenous Retinal Detachment Surgery</td>
<td>348</td>
</tr>
<tr>
<td></td>
<td>Techniques for Surgical Repair of Retinal Detachments</td>
<td>349</td>
</tr>
<tr>
<td></td>
<td>Outcomes Following Retinal Reattachment Surgery</td>
<td>353</td>
</tr>
<tr>
<td></td>
<td>Complications of Pars Plana Vitrectomy</td>
<td>354</td>
</tr>
<tr>
<td></td>
<td>Intravitreal Injections</td>
<td>355</td>
</tr>
<tr>
<td></td>
<td>Basic Texts</td>
<td>357</td>
</tr>
<tr>
<td></td>
<td>Related Academy Materials</td>
<td>359</td>
</tr>
<tr>
<td></td>
<td>Requesting Continuing Medical Education Credit</td>
<td>361</td>
</tr>
<tr>
<td></td>
<td>Study Questions</td>
<td>363</td>
</tr>
<tr>
<td></td>
<td>Answer Sheet for Section 12 Study Questions</td>
<td>373</td>
</tr>
<tr>
<td></td>
<td>Answers</td>
<td>375</td>
</tr>
<tr>
<td></td>
<td>Index</td>
<td>381</td>
</tr>
</tbody>
</table>
General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

Organization of the Course
The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

1. Update on General Medicine
2. Fundamentals and Principles of Ophthalmology
3. Clinical Optics
4. Ophthalmic Pathology and Intraocular Tumors
5. Neuro-Ophthalmology
6. Pediatric Ophthalmology and Strabismus
7. Orbit, Eyelids, and Lacrimal System
8. External Disease and Cornea
9. Intraocular Inflammation and Uveitis
10. Glaucoma
11. Lens and Cataract
12. Retina and Vitreous
13. Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

References
Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.
These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.

**Videos**

This edition of Section 12, *Retina and Vitreous*, includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty and are available to readers of the print and electronic versions of Section 12. Mobile-device users can scan the QR code below (a QR-code reader must already be installed on the device) to access the video content.

**Study Questions and CME Credit**

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

**Conclusion**

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.
Objectives

Upon completion of BCSC Section 12, *Retina and Vitreous*, the learner should be able to

- describe the basic structure and function of the retina and its relationship to the pigment epithelium, choroid, and vitreous
- select appropriate methods of examination and ancillary studies for the diagnosis of vitreoretinal disorders
- identify specific pathologic processes that affect the choroid, retina, or vitreous
- describe the principles of medical and surgical treatment of vitreoretinal disorders
- incorporate data from major prospective clinical trials in the management of vitreoretinal disorders whenever possible